David Gunn (D Gunn)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Venues

Alimentary pharmacology & therapeutics

Neurogastroenterology and motility

Gut

University of Nottingham

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Nottingham Aug 15 2017

United Kingdom

Clinical research fellow :: Biomedical Research Centre

Publications

David Gunn, C Yeldho, C Hoad, A Menys, P Gowland, L Marciani, Robin C Spiller
Mechanisms underlying the laxative effect of lactulose: A randomized placebo-controlled trial showing increased small bowel water and motility unaltered by the 5-HT 3 receptor antagonist, ondansetron. Neurogastroenterology and motility 36 (4) (2024)
David Gunn, C Yeldho, C Hoad, A Menys, P Gowland, L Marciani, Robin C Spiller
Mechanisms underlying the laxative effect of lactulose: A randomized placebo-controlled trial showing increased small bowel water and motility unaltered by the 5-HT 3 receptor antagonist, ondansetron. Neurogastroenterology and motility 36 (4) (2024)
David Gunn, C Yeldho, C Hoad, A Menys, P Gowland, L Marciani, Robin C Spiller
Mechanisms underlying the laxative effect of lactulose: A randomized placebo-controlled trial showing increased small bowel water and motility unaltered by the 5-HT 3 receptor antagonist, ondansetron. Neurogastroenterology and motility (2024)
David Gunn, C Yeldho, C Hoad, A Menys, P Gowland, L Marciani, Robin C Spiller
Mechanisms underlying the laxative effect of lactulose: A randomized placebo-controlled trial showing increased small bowel water and motility unaltered by the 5-HT 3 receptor antagonist, ondansetron. Neurogastroenterology and motility (2024)
David Gunn, Alexander Charles Ford, Amanda Farrin, Robin C Spiller
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply. Alimentary pharmacology & therapeutics 57 (11) (2023)
David Gunn, Alexander Charles Ford, Amanda Farrin, Robin C Spiller
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply. Alimentary pharmacology & therapeutics 57 (11) (2023)
David Gunn, Rabia Topan, Lorna Barnard, Ron Fried, Ivana Holloway, Richard Brindle, Maura Corsetti, Mark Scott, Adam Farmer, Kapil Kapur, David Sanders, Maria Eugenicos, Nigel Trudgill, Peter Whorwell, John T McLaughlin, Ayesha Akbar, Lesley A Houghton, Phil G Dinning, Qasim Aziz, Alexander Charles Ford, Amanda J Farrin, Robin C Spiller
Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary pharmacology & therapeutics (2023)
David Gunn, Zainab Abbas, Hannah C Harris, Giles Major, Caroline Hoad, Penny Gowland, Luca Marciani, Samantha K Gill, Fred J Warren, Megan Rossi, Jose Maria Remes-Troche, Kevin Whelan, Robin C Spiller
Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut (2021)
David Gunn, Klara Garsed, Ching Lam, Gulzar Singh, Melanie Lingaya, Verena Wahl, Beate Niesler, Amanda Henry, Ian Hall, Peter Whorwell, Robin C Spiller
Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer? Authors' reply. Alimentary pharmacology & therapeutics 50 (7) (2020)
David Gunn, Klara Garsed, Ching Lam, Gulzar Singh, Melanie Lingaya, Verena Wahl, Beate Niesler, Amanda Henry, Ian P Hall, Peter J Whorwell, Robin C Spiller
Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron. Alimentary pharmacology & therapeutics 50 (5) (2019)

David Gunn.css-eqlu8i{font-size:small;padding-left:4px;} (D Gunn)

Publication Activity (10 Years)

Top Topics

Top Venues

David Gunn (D Gunn)